- Home
- SKT vs VKTX Comparison
SKT vs VKTX Comparison
Compare SKT & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SKT | VKTX |
|---|---|---|
| Founded | 1981 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 3.3B |
| IPO Year | 1994 | 2014 |
Fundamental Metrics
Financial Performance| Metric | SKT | VKTX |
|---|---|---|
| Price | $40.50 | $38.04 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | $37.17 | ★ $95.86 |
| AVG Volume (30 Days) | 952.7K | ★ 2.5M |
| Earning Date | 04-30-2026 | 04-29-2026 |
| Dividend Yield | ★ 3.18% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.24 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $0.37 | N/A |
| Revenue Next Year | $3.90 | N/A |
| P/E Ratio | $171.29 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $29.24 | $22.96 |
| 52 Week High | $41.20 | $43.15 |
Technical Indicators
Market Signals| Indicator | SKT | VKTX |
|---|---|---|
| Relative Strength Index (RSI) | 64.26 | 73.64 |
| Support Level | $35.18 | $33.65 |
| Resistance Level | $41.03 | $39.78 |
| Average True Range (ATR) | 0.94 | 1.92 |
| MACD | 0.13 | 1.07 |
| Stochastic Oscillator | 80.21 | 87.55 |
Price Performance
Historical ComparisonAbout SKT Tanger Inc.
Tanger Inc is an owner and operator of outlet and open-air centers in the United States and Canada. It is a fully-integrated, self-administered and self-managed REIT, which focuses on developing, acquiring, owning, operating and managing outlet and open-air shopping centers. Its consolidated portfolio consisted of 31 outlet centers and 2 open-air lifestyle centers.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.